- Home
- MYGN vs SYRE Comparison
MYGN vs SYRE Comparison
Compare MYGN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- SYRE
- Stock Information
- Founded
- MYGN 1991
- SYRE 2013
- Country
- MYGN United States
- SYRE United States
- Employees
- MYGN N/A
- SYRE N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- SYRE Health Care
- Exchange
- MYGN Nasdaq
- SYRE Nasdaq
- Market Cap
- MYGN 1.3B
- SYRE 897.9M
- IPO Year
- MYGN 1995
- SYRE 2016
- Fundamental
- Price
- MYGN $8.80
- SYRE $15.49
- Analyst Decision
- MYGN Hold
- SYRE Strong Buy
- Analyst Count
- MYGN 15
- SYRE 8
- Target Price
- MYGN $20.43
- SYRE $51.50
- AVG Volume (30 Days)
- MYGN 875.3K
- SYRE 668.6K
- Earning Date
- MYGN 05-06-2025
- SYRE 05-08-2025
- Dividend Yield
- MYGN N/A
- SYRE N/A
- EPS Growth
- MYGN N/A
- SYRE N/A
- EPS
- MYGN N/A
- SYRE N/A
- Revenue
- MYGN $837,600,000.00
- SYRE N/A
- Revenue This Year
- MYGN $3.03
- SYRE N/A
- Revenue Next Year
- MYGN $8.31
- SYRE N/A
- P/E Ratio
- MYGN N/A
- SYRE N/A
- Revenue Growth
- MYGN 11.21
- SYRE N/A
- 52 Week Low
- MYGN $8.53
- SYRE $14.90
- 52 Week High
- MYGN $29.30
- SYRE $40.84
- Technical
- Relative Strength Index (RSI)
- MYGN 27.06
- SYRE 33.68
- Support Level
- MYGN $8.53
- SYRE $16.71
- Resistance Level
- MYGN $10.30
- SYRE $18.28
- Average True Range (ATR)
- MYGN 0.44
- SYRE 1.17
- MACD
- MYGN -0.01
- SYRE -0.17
- Stochastic Oscillator
- MYGN 15.08
- SYRE 12.83
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.